Tekla Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Tekla Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-382,237	Closed	-$2.6M	–	200
2021 Q2	$2.6M	Hold	382,237	–	–	0.08%	146
2021 Q1	$3.93M	Buy	+382,237	New	+$4.19M	0.14%	133
2019 Q2	–	Sell	-10,127	Closed	-$63K	–	205
2019 Q1	$63K	Hold	10,127	–	–	﹤0.01%	192
2018 Q4	$34K	Hold	10,127	–	–	﹤0.01%	202
2018 Q3	$66K	Hold	10,127	–	–	﹤0.01%	210
2018 Q2	$78K	Hold	10,127	–	–	﹤0.01%	179
2018 Q1	$226K	Buy	+10,127	New	+$225K	0.01%	185

Other funds holding JNCE

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Tekla Capital Management's JNCE Position: Q3 2021 in Review

Tekla Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2021, closing a stake of 382,237 shares — an estimated $2.6M sold.

Tekla Capital Management first reported a position in JNCE in Q1 2018 and held it in 7 quarters. The position peaked at $3.93M in Q1 2021. 115 funds tracked by Wall St. Rank hold JNCE as of Q3 2021.

Tekla Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Tekla Capital Management sold 382,237 Jounce Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $2.6M.
Tekla Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Tekla Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.93M in Q1 2021.
115 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.